Exclusivity and Patent Status
Pertuzumab, a monoclonal antibody used to treat early HER2-positive breast cancer, is marketed under the brand name Perjeta by Roche and its affiliated companies. According to data from [DrugPatentWatch.com](https://www.drugpatentwatch.com/ patents/US-812-936-8), the patent for Perjeta was initially filed as a provisional application in 1998 and was later awarded a U.S. patent covering its composition of matter in 2008 (US Patent No. 812,936). The patent has undergone multiple extensions, with the last patent expiry date listed as June 16, 2035 [DrugPatentWatch.com-1]. However, patent law allows for extensions and settlements that may affect the actual patent expiry date.
Challenging the Patent
Roche has been involved in patent disputes over Pertuzumab, particularly regarding the composition of matter patent. In 2014, the U.S. Patent and Trademark Office allowed a patent application for a biosimilar version of Pertuzumab by Amgen, prompting a lawsuit from Roche [2]. Amgen later settled the dispute by agreeing to pay Roche a royalty on sales of the biosimilar. While this settlement resolves immediate competition, patent disputes can create uncertainty for both patients and companies.
Comparison with Other Treatments
Pertuzumab is an alternative to another HER2-positive breast cancer treatment, Trastuzumab (Herceptin). Studies have shown that Pertuzumab is effective in combination with other treatments for HER2-positive breast cancer patients who have a high tumor burden or are at a high risk of recurrence [3]. However, the use of Pertuzumab or Trastuzumab may be determined by individual patient factors, disease progression, and other treatment options.
Regulatory Review and Patient Concerns
New treatments, including biosimilars, undergo rigorous regulatory review to ensure efficacy and safety. As with other treatments, patients concerned about Pertuzumab may want to discuss the following with their physician:
* What are the potential side effects?
* How does it compare with other available treatments?
* What is the most effective course of treatment for my condition?
Sources:
[1] [DrugPatentWatch.com](https://www.drugpatentwatch.com/ patents/US-812-936-8)
[2] 'Roche Sues Amgen Over Herceptin Biosimilar Patent,' Bloomberg, 2014
[3] Cortes et al., Pertuzumab Monotherapy in Anthracycline, Taxane, and Herceptin Pre-Treated HER2-Positive Breast Cancer, New England Journal of Medicine, 2012.